arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

GRAIL, Inc.

GRAL
$69.45 ▲ +6.12 (+9.66%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
5 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

GRAIL, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $2.6B
Dividend Yield
Revenue Growth 17.2%
Op. Margin -382.0%
ROIC -16.7%
FCF / Share $-8.16
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$147.17M
↑ +17.2%
Net Income Profit after all expenses
$-408.35M
↑ +79.9%
FCF / Share Free cash flow per share
$-8.16
↑ +55.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
30
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 14 quarters